ClinicalTrials.gg
CompletedNCT02086929Updated Dec 30, 2015

Trazodone Once a Day in Major Depression Disorder

A Phase 3 interventional study of Trazodone and Venlafaxine in Major Depressive Disorder, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Completed at 32 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-12-30.

Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
364
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Depressive Disorder, Major with a site in Czechia — 10 open to participants now, 10 under way, 4 of them phase 3. Depressive Disorder, Major · Czechia.

Enrollment
27th of 47
364 · median 400
Started
2012
with 1 other
Phase 3
27 of 47
4 open now
Registered
13th of 47
by date

Among the 47 studies in Depressive Disorder, Major with a site in Czechia, this one is the 27th largest by enrollment, is one of 2 that started in 2012, is one of 27 in phase 3, and was the 13th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

10 of the 47 studies in Depressive Disorder, Major with a site in Czechia are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Depressive Disorder, Major with a site in Czechia, or all of them as a file.
02

Study summary

The study objective is to evaluate the efficacy and safety of trazodone OAD vs venlafaxine extended release (venlafaxine XR) after an 8-week treatment period in patients with major depressive disorder.

Read the detailed description

This randomized, venlafaxine-controlled, double-blind, parallel design study consists of a Pre-Treatment Phase (screening, wash-out) and a double-blind Treatment Phase (randomization to trazodone OAD or to venlafaxine XR, treatment for 8 weeks and tapering for 1 to 3 weeks). During the Pre-Treatment Phase, patients who sign an informed consent form will undergo initial screening. Potential candidates will be instructed to discontinue antidepressants or prohibited medications (wash-out) for a period specific to taper schedule (based on 5 elimination half-lives of the used medication). On the last day of the Pre-Treatment Phase, patients will be evaluated for the final eligibility, and those qualified will be randomly allocated in a 1:1 proportion to trazodone OAD 300 mg/day (1 week of tapering with trazodone OAD 150 mg/day) or to venlafaxine XR 75 mg/day once daily. After 3 and 5 weeks of treatment, subjects will be evaluated for the response. For non responding patients dose increases (in increments of 75 mg/day) will be done till to reach the maximum of 225 mg/day for venlafaxine XR and 450 mg/day for trazodone OAD. Patients non responding to treatment at the final visit will have their study medication tapered from 1 to 3 weeks, according to the maximum dose reached during the study. In order to prevent relapse of depression symptoms, responders at the final visit may continue the treatment. In this case, an unblinded third party Dispenser will open the treatment code and will prescribe the same medication taken by the patients during the trial, according to the formulation available on the market.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Trazodone
  • Venlafaxine
  • Major depressive disorder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • men and women 18-75 years of age (limits included) with no limitation of race;
  • outpatients;
  • major depressive disorder according to criteria as assessed using the MINI International Neuropsychiatric Interview;
  • 17-item HAMD score > 18 at both screening and baseline visits with a decrease not exceeding 20% between screening and baseline;
  • symptoms of depression for at least one month before study entry (screening visit);
  • legally capable to give their consent to participate the study, and available to sign and date the written prior to the inclusion in the study;
  • women of must agree not to start a pregnancy from the signature of the informed consent up to 30 days after the last administration of the product.

Exclusion criteria

Exclusion Criteria:

  • participation in another trial involving any drug during the past 60 days;
  • known to venlafaxine or trazodone or their ;
  • use of venlafaxine or trazodone within the previous six months;
  • acute, or chronic, or recurrent medical conditions that might affect/jeopardize the study results;
  • significant liver disease, defined as active hepatitis or elevated liver enzymes > 3 times the upper boundary of the normal range;
  • significant renal disease, defined as urea and/or creatinine > 3 times the upper boundary of the normal range
  • myocardial infarction within 6 months prior to start of the double blind treatment;
  • positive present history of glaucoma;
  • history of risk factors for Torsade de Pointes, such as heart failure, cardiac arrhythmias, bradycardia, cardiac conduction abnormalities, family history of long syndrome, cardiac hypertrophy, cardiomyopathy, chronic cardiac insufficiency;
  • values of electrolytes (sodium, potassium, calcium, magnesium, chloride) outside the normal laboratory range and judged by the Investigator;
  • concomitant treatment with drugs known for QT prolongation, or with drugs producing hypokalemia, or diuretics;
  • QTcF values higher than 450 msec in the performed at the screening;
  • history of major depression resistant to medical treatments (previous failure to respond to two consecutive antidepressants of different classes used for a sufficient length of time at appropriate doses);
  • history of seizure events other than a single childhood febrile seizure;
  • history of alcohol or psychoactive substance abuse or addiction (except caffeine or nicotine) during the last year as defined by criteria;
  • positive urine drug screen for CNS-active drugs (cocaine, opioids, amphetamines and cannabinoids) at Visit 1 (screening);
  • acute risk of suicide (HAMD, criterion 3 with a value > 3);
  • presence of any primary psychiatric disorder other than major depression;
  • history or presence of bipolar disorder, any psychotic disorder, mental disorder due to general medical conditions;
  • pregnancy, lactation, or female with a positive urine pregnancy test result at Visit 1 (Screening);
  • electroconvulsive therapy (ECT) within 30 days prior to the screening visit;
  • use of antipsychotic drugs within two months prior to the baseline visit (Visit 2);
  • use of any anxiolytic or sedative hypnotic drug within seven days prior to the baseline (Visit 2) and during the study. Exception is stable low doses of benzodiazepines for insomnia (if taken by the patient more than two weeks before the Treatment Phase);
  • use of any psychotropic drug or substance with central nervous system effects within seven days prior to the baseline visit (Visit 2);
  • use of any non-psychotropic drug with psychotropic effects (e.g. alpha-adrenergic blockers) within seven days prior to the baseline visit (visit 2), unless a stable dose of the drug has been maintained for at least one month (three months for thyroid or hormonal medications) before the baseline visit (visit 2);
  • concomitant treatment with inhibitors (e.g. ketoconazole, ritonavir, indinavir);
  • hyperthyroidism, even if pharmacologically corrected;
  • start or discontinuation of psychotherapy within 6 weeks prior to screening;
  • clinically significant abnormalities on physical examination, vital signs, ECG, laboratory tests at the screening visit;
  • high blood pressure (supine systolic blood pressure > 160 mmHg or supine diastolic blood pressure > 90 mmHg) at screening or baseline, either untreated or under treatment with antihypertensives
  • inability to comply with the protocol requirements, instructions and study-related restrictions; e.g. uncooperative attitude, inability to return for study-visits, and improbability of completing the clinical study;
  • vulnerable subjects (e.g. persons kept in detention);
  • if subject is the Investigator or his/her deputies, first grade relative, research assistant, pharmacist, study coordinator, other staff of relative thereof directly involved in the conduct of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
364 participants (actual)

Study arms

  • Experimental
    Trazodone

    300 mg/day for 8 weeks (including 1 week 150 mg/day of dose-titration). After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 450 mg/day. Dosage form: capsule.

    Drug: Trazodone

  • Active comparator
    Venlafaxine XR

    75 mg/die for 8 weeks. After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 225 mg/day. Dosage form: capsule.

    Drug: Venlafaxine

Interventions

06

What researchers measure

Primary outcomes

  1. Hamilton Depression Rating Scale (HAMD) score

    Mean change from baseline (Day 0) in HAMD score at Day 56.

    Time frame: Day 56

Secondary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS) score

    Mean change from baseline (Day 0) in MADRS score at Day 56.

    Time frame: Day 56

  2. Clinical Global Impression (CGI) Severity of Illness score

    CGI-Severity of Illness improvement at Day 56.

    Time frame: Day 56

  3. Clinical Global Impression (CGI) Global improvement score

    CGI-Global improvement at Day 56.

    Time frame: Day 56

  4. Percentage of responders

    Rate of patients with a 50% decrease with respect to baseline on the HAMD score at Day 56.

    Time frame: Day 56

  5. Percentage of patients with remission

    Rate of patients with a HAMD score \<or= at Day 56.

    Time frame: Day 56

  6. Safety profile of trazodone OAD compared to venlafaxine XR

    Safety and tolerability will be assessed through adverse events monitoring, physical examinations and monitoring of vital signs, body weight, clinical laboratory tests, ECG.

    Time frame: 11 weeks

07

Study locations

32 sites
  • Institute für Psychosomatik
    Vienna, 1010, Austria
  • AKH Wien
    Vienna, 1090, Austria
  • PRAGTIS, s.r.o.
    Praha 2, Praha 12000, Czech Republic
  • Psychiatry Trial, s.r.o.
    Praha 5, Praha 15800, Czech Republic
  • MEDICAL SERVICES PRAGUE, s.r.o.
    Praha 6, Praha 160 00, Czech Republic
  • Neuropsychiatrie s.r.o.
    Praha 6, Praha 160 00, Czech Republic
  • Saint Anne, s.r.o.
    Brno-mesto, 60200, Czech Republic
  • SUPERVIZE, s.r.o.
    Kutna Hora, 284 01, Czech Republic
  • BIALBI s.r.o.
    Litomerice, 41201, Czech Republic
  • Fakultni Nemocnice Olomouc, Klinika Psychiatrie
    Olomouc, 77 900, Czech Republic
  • MUDr. Eva Soukupová-Psychiatrická praxe, s.r.o.
    Plzeň, 301 00, Czech Republic
  • NZZ- MUDr. Jaroslav Hronek, psychiatrická ambulance
    Plzeň, 301 00, Czech Republic
  • UOPI di Psichiatria Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Presidio "Gaspare Rodolico"
    Catania, 95100, Italy
  • Clinica Psichiatrica Nuovo Ospedale S. Salvatore Università degli Studi del L'Aquila
    L'Aquila, 67100, Italy
  • Ospedale Santa Maria della Misericordia Unità di Degenza Psichiatrica-SPDC
    Perugia, 06132, Italy
  • Azienda Ospedaliera Sant'Andrea Università La Sapienza Unità Operativa Complessa di Psichiatria
    Rome, 00189, Italy
  • AOUS-Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte Clinica Psichiatrica Universitaria
    Siena, 53100, Italy
  • Department of Neurosciences University of Turin
    Turin, 10126, Italy
  • Quantum Medical Center Srl
    Bucharest, RO-011426, Romania
  • Spitalul clinic de psihiatrie "Prof. Dr. Al. Obregia"/Sectia 13
    Bucharest, RO-041914, Romania
  • Spitalul Clinic de Psihiatrie "Prof. Dr. Al. Obregia"/Sectia 1
    Bucharest, RO-041914, Romania
  • Spitalul Clinc de Urgenta Militar "Dr. Stefan Odobleja", Craiova
    Craiova, RO-200530, Romania
  • Spital Clinic de Psihiatrie SOCOLA / Iasi
    Iasi, RO-700282, Romania
  • Spitalul de Psihiatrie "Dr. Gh.Preda" Sibiu
    Sibiu, RO-550082, Romania
  • Spitalul Clinc Judetean Mures, Centrul de Sanatate Mintala
    Targu Mures, RO-540096, Romania
  • Psychiatricka ambulancia
    Bratislava, 81107, Slovakia
  • MENTUM, s.r.o.
    Bratislava, 82007, Slovakia
  • EPAMED, s.r.o.
    Kosice, 4000, Slovakia
  • Psychiatricka nemocnica
    Michalovce, 7101, Slovakia
  • Psycholine, s.r.o.
    Rimavska Sobota, 97901, Slovakia
  • Psychiatricke oddelenie, NsP sv Barbory Roznava
    Roznava, 4801, Slovakia
  • Instituto de Investigacion y Asistencia Psiquiatrica - IIAP
    Madrid, 28002, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2014
First posted
Mar 13, 2014
Start
Dec 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Last update
Dec 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02086929
Responsible party
Sponsor
First posted
Mar 13, 2014
Start date
Dec 2012
Primary completion
Apr 2014
Completion
Apr 2014
Last update
Dec 30, 2015

Study contacts

Filippo Bogetto, MD
principal investigator · Department of Neuroscience University of Turin - Italy

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion